| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2019-02-21 |
详情>>
内部人交易：
LEWIS EARL R等共交易11笔
|
| 2018-11-07 |
详情>>
股本变动：
变动后总股本6668.47万股
|
| 2018-11-07 |
详情>>
业绩披露：
2018年三季报(累计)每股收益-0.05美元,归母净利润-323.5万美元,同比去年增长73.49%
|
| 2018-08-07 |
详情>>
业绩披露：
2018年中报每股收益-0.06美元,归母净利润-404.8万美元,同比去年增长-23.49%
|
| 2018-05-10 |
详情>>
业绩披露：
2018年一季报每股收益-0.02美元,归母净利润-145.9万美元,同比去年增长-22.71%
|
| 2018-04-26 |
股东大会：
将于2018-05-24召开股东大会
会议内容 ▼▲
- 1. The election of the nine nominees identified in this proxy statement to our Board of Directors.
2. An advisory vote on our named executive officers’ compensation.
3. The ratification of our Audit Committee’s selection of Ernst & Young LLP as our independent registered public accounting firm for the 2018 fiscal year.
4. The transaction of such other business as may properly come before the meeting and any adjournments or postponements.
|
| 2018-02-16 |
详情>>
业绩披露：
2017年年报每股收益-0.22美元,归母净利润-1447.3万美元,同比去年增长-203.35%
|
| 2018-02-16 |
详情>>
业绩披露：
2015年年报每股收益-0.24美元,归母净利润-1534.2万美元,同比去年增长35.93%
|
| 2017-11-08 |
详情>>
业绩披露：
2017年三季报(累计)每股收益-0.19美元,归母净利润-1220.4万美元,同比去年增长-284.5%
|
| 2017-09-22 |
股东大会：
将于2017-10-27召开股东大会
会议内容 ▼▲
- 1.To adopt the Agreement and Plan of Merger, dated August 7, 2017, as it may be amended from time to time, by and among NxStage, Fresenius Medical Care Holdings, Inc., a New York corporation, which we refer to as Fresenius, and Broadway Renal Services, Inc., a Delaware corporation and wholly-owned subsidiary of Fresenius, which we refer to as Merger Sub, pursuant to which Merger Sub would merge with and into NxStage;
2. To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to NxStage’s named executive officers in connection with the merger, as described in the accompanying proxy statement;
3.To approve an adjournment of the special meeting, if necessary, to solicit additional proxies, in the event that there are insufficient votes to approve Proposal 1 at the special meeting.
|
| 2017-08-08 |
详情>>
业绩披露：
2017年中报每股收益-0.05美元,归母净利润-327.8万美元,同比去年增长-8.98%
|
| 2017-05-09 |
详情>>
业绩披露：
2017年一季报每股收益-0.02美元,归母净利润-118.9万美元,同比去年增长6.82%
|
| 2017-04-27 |
股东大会：
将于2017-05-25召开股东大会
会议内容 ▼▲
- 1. The election of the nine nominees identified in this proxy statement to our Board of Directors.
2. An advisory vote on our named executive officers’ compensation.
3. An advisory vote on the frequency of future advisory votes on our named executive officers’ compensation.
4. The ratification of our Audit Committee’s selection of Ernst & Young LLP as our independent registered public accounting firm for the 2017 fiscal year.
5. The approval of an amendment to our Amended and Restated By-laws to adopt a majority voting standard for uncontested director elections.
6. The approval of our Amended and Restated 2014 Omnibus Incentive Plan and the material terms of this plan for purposes of Internal Revenue Code §162(m).
7. The transaction of such other business as may properly come before the meeting and any adjournments or postponements.
|
| 2017-02-28 |
详情>>
业绩披露：
2016年年报每股收益-0.07美元,归母净利润-477.1万美元,同比去年增长68.90%
|
| 2016-11-03 |
详情>>
业绩披露：
2016年三季报(累计)每股收益-0.05美元,归母净利润-317.4万美元,同比去年增长74.95%
|
| 2016-04-28 |
股东大会：
将于2016-05-26召开股东大会
会议内容 ▼▲
- 1. The election of the eight nominees identified in this proxy statement to our Board of Directors.
2. An advisory vote on our named executive officers’ compensation.
3. The ratification of our Audit Committee’s selection of Ernst & Young LLP as our independent registered public accounting firm for the 2016 fiscal year.
4. The transaction of such other business as may properly come before the meeting and any adjournments or postponements.
|
| 2015-04-23 |
股东大会：
将于2015-05-21召开股东大会
会议内容 ▼▲
- 1. The election of the eight nominees identified in this proxy statement to our Board of Directors;
2. An advisory vote on our named executive officers’ compensation;
3. The ratification of our Audit Committee’s selection of Ernst & Young LLP as our independent registered public accounting firm for the 2015 fiscal year;
4. The approval of an amendment to our 2005 Employee Stock Purchase Plan to increase the number of shares that may be issued pursuant to the plan by an additional 200,000 shares;
5. The transaction of such other business as may properly come before the meeting and any adjournments or postponements.
|
| 2014-04-24 |
股东大会：
将于2014-05-22召开股东大会
会议内容 ▼▲
- 1. The election of the nine nominees identified in this proxy statement to our Board of Directors;
2. An advisory vote on our named executive officers’ compensation;
3. The ratification of our Audit Committee’s selection of Ernst & Young LLP as our independent registered public accounting firm for the 2014 fiscal year;
4. The approval of an amendment to our Amended and Restated By-laws to adopt a majority voting standard for uncontested director elections;
5. The approval of our 2014 Omnibus Incentive Plan and §162(m) material terms for payment;
6. The transaction of such other business as may properly come before the meeting and any adjournments or postponements.
|
| 2013-04-26 |
股东大会：
将于2013-05-23召开股东大会
会议内容 ▼▲
- 1. the election of eight members to our Board of Directors;
2. an advisory vote on approval of our named executive officers’ compensation;
3. the ratification of the selection by our Audit Committee of Ernst & Young LLP as our independent registered public accounting firm for the 2013 fiscal year;
4. the transaction of such other business as may properly come before the meeting or any adjournment thereof.
|